OmniComm Systems® Forms Reseller Agreement with Tri-I Biotech Shanghai
OmniComm Systems, a global provider of clinical data management technology and services, announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai Inc.
OmniComm Systems, a global provider of clinical data management technology and services, announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai Inc., a China based consultancy providing high performance informatics solutions to over 1,000 medical and clinical research organizations across China, Hong Kong, Macau and Taiwan.
The partnership with Tri-I allows us to bring Omnicomm’s Phase I unit automation solution TrialOne to clinical pharmacology centers and Phase I units across China, with implementation services and after sales support in the local language.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
